(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of -5.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Voyager Therapeutics's revenue in 2024 is $119,044,000.On average, 4 Wall Street analysts forecast VYGR's revenue for 2024 to be $2,819,765,676, with the lowest VYGR revenue forecast at $1,822,186,538, and the highest VYGR revenue forecast at $4,016,425,492. On average, 3 Wall Street analysts forecast VYGR's revenue for 2025 to be $4,470,938,647, with the lowest VYGR revenue forecast at $543,936,280, and the highest VYGR revenue forecast at $8,653,482,279.
In 2026, VYGR is forecast to generate $5,366,203,370 in revenue, with the lowest revenue forecast at $4,052,325,286 and the highest revenue forecast at $6,680,081,455.